drugset / Trial / NCT07256236
SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is a prospective, single arm II clinical trial. The main objective of the study is to evaluate the efficacy and safety of the combination of Sacituzumab Tirumotecan (SKB264) and QL1706 in the treatment of recurrent or metastatic cervical cancer.
Timeline
- Start
- 2026-01-28
- Primary completion
- 2028-06-30
- Completion
- 2028-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QL1706 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Sacituzumab Tirumotecan | Other / unclassified | 4 mg/kg | Intravenous |